Mustang Bio
MBIO0.56000.36% ( -0.0020 )
Mustang Bio (MBIO)
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune di...
- Open
- 0.5700
- High
- 0.5735
- Low
- 0.5600
- Prev. Close
- 0.5620
- Volume
- 7.98K
- Turnover
- 4.60K
- Avg Price
- 0.5768
- Bid/Ask Ratio
- --
- Amplitude
- 2.40%
- 52wk High
- 2.0890
- Volume Ratio
- 0.39
- Turnover Ratio
- 0.15%
Mustang Bio Analyst Rating
View MoreForecast & Rating
Jul 5, 2024Price forecast
$100.0017757.14%
Forecast & RatingBuy
1analysts
- Strong buy0.00%
- Buy100.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- benzinga_article · Jun 5 at 04:06 PM
12 Health Care Stocks Moving In Friday's After-Market Session
- prnewswire · May 8 at 10:45 AM
11:44 ETAdvaita Bio představuje iSCanGuide™: Integrovanou analýzu jednobuněčné a prostorové transkriptomiky využívající infrastrukturu s GPU akcelerací
- prnewswire · May 7 at 06:45 AM
07:45 ETAdvaita Bio Launches iSCanGuide™: Unified Single-Cell and Spatial Transcriptomics Analysis, Powered by GPU-Accelerated Infrastructure
- MorningStar · May 5 at 09:20 AM
Creatv Announces Five Clinical Data Presentations at ASCO 2026
- Forbes · May 1 at 11:01 AM
An 8-Hour AI Result Is Testing Pharma’s $10 Billion Royalty Market
- prnewswire · Apr 29 at 10:14 PM
23:13 ETD3 Bio Presents KRAS Pipeline Updates at AACR 2026; Elisrasib (D3S-001), a Next-Generation KRAS G12C Inhibitor, Shows Strong Phase 2 Efficacy Across Multiple Tumor Types
